Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial

COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in no...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Circulation (New York, N.Y.) Ročník 147; číslo 25; s. 1891
Hlavní autori:	Piazza, Gregory, Spyropoulos, Alex C, Hsia, Judith, Goldin, Mark, Towner, William J, Go, Alan S, Bull, Todd M, Weng, Stephen, Lipardi, Concetta, Barnathan, Elliot S, Bonaca, Marc P
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 20.06.2023
Predmet:	Anticoagulants - adverse effects COVID-19 Hemorrhage - chemically induced Hemorrhage - drug therapy Hospitalization Humans Outpatients Rivaroxaban - adverse effects Thrombosis - epidemiology Thrombosis - prevention & control COVID-19 pre-exposure prophylaxis prevention and control rivaroxaban thrombosis venous thromboembolism
ISSN:	1524-4539, 1524-4539
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!